Cisplatin Cancer Research Results

Cisplatin, Cisplatin: Click to Expand ⟱
Features:
Cisplatin is a chemotherapy medication used to treat various types of cancer. It is a platinum-based drug that works by interfering with the DNA of cancer cells, preventing them from reproducing and ultimately leading to cell death.
Cisplatin (cis-diamminedichloroplatinum II; CDDP) is a platinum-based chemotherapeutic agent that forms covalent DNA crosslinks, primarily intrastrand adducts at adjacent guanine bases. These distort DNA structure, block replication and transcription, and activate DNA damage response pathways (ATM/ATR → p53), leading to cell-cycle arrest and apoptosis. Secondary mechanisms include ROS generation, stress MAPK activation, and modulation of NF-κB. Clinical resistance frequently involves enhanced DNA repair (ERCC1/NER), altered drug transport (CTR1, ATP7A/B), and increased antioxidant defenses. Major toxicities include nephrotoxicity, ototoxicity, and peripheral neuropathy.

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 DNA crosslink formation (intrastrand adducts) DNA adducts ↑; replication block ↑ Normal dividing cells also affected P, R, G Direct DNA cytotoxicity Cisplatin forms covalent intrastrand crosslinks (primarily at adjacent guanines), distorting DNA and blocking replication and transcription.
2 DNA damage response (ATM / ATR → p53) Checkpoint activation ↑; p53 signaling ↑ ↔ (toxicity in proliferating tissues) R, G Damage signaling cascade DNA distortion activates ATM/ATR pathways leading to p53-mediated cell-cycle arrest and apoptosis.
3 Intrinsic apoptosis (mitochondrial pathway) Bax ↑; Bcl-2 ↓; caspase-9/3 ↑ Nephrotoxicity & ototoxicity risk G Execution of cell death Persistent DNA damage triggers mitochondrial outer membrane permeabilization and caspase activation.
4 Cell-cycle arrest (G2/M emphasis) G2/M arrest ↑ ↔ G Cytostasis → apoptosis Cells accumulate in G2/M phase due to unrepaired DNA lesions.
5 ROS generation / oxidative stress ROS ↑ (secondary mechanism) Oxidative injury ↑ (kidney, cochlea) R, G Stress amplification Cisplatin increases mitochondrial ROS and oxidative stress, contributing to cytotoxicity and organ toxicity.
6 MAPK signaling (JNK / p38 activation) Stress MAPK activation ↑ ↔ R, G Stress-response signaling JNK and p38 activation contribute to apoptosis and stress signaling.
7 NF-κB activation (resistance axis) NF-κB ↑ may promote survival ↔ R, G Resistance modulation NF-κB activation can reduce sensitivity; inhibition enhances cytotoxicity in some models.
8 DNA repair pathways (NER / ERCC1) NER ↑ → resistance — G Resistance determinant Nucleotide excision repair (ERCC1) removes platinum adducts; high ERCC1 correlates with resistance.
9 Drug transport (CTR1 uptake; ATP7A/B efflux) CTR1 ↓ or ATP7A/B ↑ → resistance — G Exposure constraint Copper transporters influence intracellular cisplatin accumulation and resistance.
10 Clinical toxicity profile — Nephrotoxicity, ototoxicity, neurotoxicity — Translation constraint Major dose-limiting toxicities arise from DNA damage and oxidative stress in normal tissues.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (DNA aquation and initial adduct formation)
  • R: 30 min–3 hr (checkpoint activation / stress signaling)
  • G: >3 hr (apoptosis, phenotype outcomes, resistance development)
Scientific Papers found: Click to Expand⟱
7871- isoO,  Cisplatin,    Isoorientin reverses lung cancer drug resistance by promoting ferroptosis via the SIRT6/Nrf2/GPX4 signaling pathway
- vitro+vivo, Lung, NA
ChemoSen↑, i-Iron↑, i-MDA↑, *i-ROS↑, GSH↓, Ferroptosis↑, NRF2↓, GPx4↓, SIRT6↓,
9231- ITCs,  Cisplatin,  AITC,  BITC,    Isothiocyanates inhibit the cisplatin-induced apoptosis and inflammation in human kidney HEK-293 cells
- in-vitro, Nor, HEK293
*ROS↓, *NO↓, *chemoP↑, *MAPK↓, *Bax:Bcl2↓, *Apoptosis↓, *RenoP↑,
8051- IVM,  Cisplatin,  rMETase,    Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts
- in-vitro, Lung, A549
Dose↝, ChemoSen↑, selectivity↑,
8067- KAE,  Cisplatin,    Kaempferol Induces Cell Death and Sensitizes Human Head and Neck Squamous Cell Carcinoma Cell Lines to Cisplatin
- in-vitro, HNSCC, NA
AntiCan↑, OCR↓, i-ATP↓, TumCMig↓, TumCP↓, Apoptosis↑, ChemoSen↑,
8225- LCA,  Cisplatin,    Licochalcone A protects against cisplatin-induced acute kidney injury via the modulation of Nrf2/Keap1-mediated ferroptosis and apoptosis
- in-vivo, Nor, NA
*RenoP↑, *Urea↓, *BUN↓, *creat↓, *Apoptosis↓, *Ferroptosis↓, *Iron↓, *ROS↓, *lipid-P↓, *mtDam↓, *NRF2↑,
8289- LE,  Cisplatin,    Effects of Glycyrrhizin in a Mouse Model of Lung Adenocarcinoma
- vitro+vivo, Lung, NA
TBXAS1/TxAS↓, PCNA↓, Weight?, RenoP↑, hepatoP↑,
8276- LE,  Cisplatin,    Glycyrrhizin enhances the antitumor activity of cisplatin in non‑small cell lung cancer cells by influencing DNA damage and apoptosis
- in-vitro, NSCLC, NA
tumCV↓, ChemoSen↑, Apoptosis↑, TumCCA↑, Bcl-xL↑, cl‑Casp↑, γH2AX↑, P53↑,
1064- LT,  Cisplatin,    Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells
- vitro+vivo, Lung, LNM35 - in-vitro, CRC, HT-29 - in-vitro, Liver, HepG2 - in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
Casp3↑, Casp7↑, HDAC↓,
8406- LT,  Cisplatin,    Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase–mediated p53 phosphorylation and stabilization
- vitro+vivo, Liver, HepG2 - in-vitro, Laryn, HEp2
ChemoSen↑, Dose↝, P53↑,
8376- LT,  Cisplatin,    Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization
- vitro+vivo, Var, NA
ChemoSen↑, JNK↑, P53↑,
8342- Lut,  Cisplatin,    Lutein Influences Cisplatin Sensitivity Through Differential Regulation of DNA Damage Response Genes in Breast Cancer Cells
- in-vitro, Nor, HUVECs - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
tumCV↓, DNAdam↑, selectivity↑, ROS↑, Casp3↑, BRCA1↓, Ku70/XRCC6↓, XRCC1↓, ChemoSen↑, NA↓,
4781- Lyco,  5-FU,  Chemo,  Cisplatin,    Antioxidant and anti-inflammatory activities of lycopene against 5-fluorouracil-induced cytotoxicity in Caco2 cells
- in-vitro, Colon, Caco-2
chemoP↑, Inflam↓, COX2/PTGS2↓, IL1β↓, IL6↓, TNF-α↓, ROS↑, ChemoSen↑, SOD↓,
4518- MAG,  Cisplatin,    Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells
- in-vitro, GC, MKN45
ChemoSen↑, tumCV↓, BAX↑, Bcl-2↓, P21↑, P53↑, MMP9↓,
4532- MAG,  Cisplatin,    Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation
- in-vivo, Var, NA
cachexia↓, *IGF-1↑, chemoP↑, *M2 MC↑,
8577- Matr,  Cisplatin,    Meta analysis of compound matrine injection combined with cisplatin chemotherapy for advanced gastric cancer
- Review, GC, NA
ChemoSen↑, QoL↑, chemoP↑,
8528- Matr,  Cisplatin,    Matrine targets Enolase 1 and regulates the glycolysis-lactylation axis to enhance cisplatin sensitivity in triple-negative breast cancer
- vitro+vivo, BC, NA
ChemoSen↑, ENO1↓, Glycolysis↓, lactateProd↓,
8653- MBZ,  Cisplatin,    Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)
- in-vitro, HNSCC, CAL27 - in-vitro, HNSCC, SCC-154
TumCP↓, TumCCA↑, TumCMig↓, Apoptosis↑, ChemoSen↑,
8719- MeJa,  Cisplatin,  Rad,    Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation
- in-vitro, Cerv, SiHa - in-vitro, Cerv, CaSki - in-vitro, Cerv, HeLa - in-vitro, Cerv, C33A
RadioS↑, ChemoSen↑,
8760- MeSA,  Cisplatin,    Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer
- vitro+vivo, Lung, NA - in-vitro, Pca, NA
PD-L1↓, ChemoSen↑, T-Cell↑,
8464- Mg,  Cisplatin,    Efficacy of Prophylactic Magnesium Therapy for the Prevention of Cisplatin-Induced Renal Injury: A Meta-Analysis
- Review, Var, NA
RenoP↑, Dose↝, eff↝,
8659- MLT,  Cisplatin,    Melatonin Sensitizes OVCAR-3 Cells to Cisplatin through Suppression of PI3K/Akt Pathway
- in-vitro, Ovarian, OVCAR-3
Dose?, ROS↑, cl‑Casp3↑, p‑Akt↓, ChemoSen↑, Apoptosis↑, PI3K↓, Akt↓,
8900- MOR,  Cisplatin,    Morin Hydrate Mitigates Cisplatin-Induced Renal and Hepatic Injury by Impeding Oxidative/Nitrosative Stress and Inflammation in Mice
- in-vivo, Nor, NA
Dose↝, RenoP↑, *ROS↓, *TAC↑, *Inflam↓,
8882- MOR,  Cisplatin,    Morin hydrate protects against cisplatin-induced testicular toxicity by modulating ferroptosis and steroidogenesis genes' expression and upregulating Nrf2/Heme oxygenase-1
- in-vivo, Nor, NA
*antiOx↑, *Inflam↓, *Apoptosis↓, *Dose?, *SOD↑, *GPx↑, *NRF2↑, *HO-1↑, *MDA↓, *other↑, *Ferroptosis↓, *Iron↓, *ROS↓, *other↓, ChemoSen↑, *chemoP↑, *selectivity↑,
8895- MOR,  Cisplatin,    Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
- in-vitro, Ovarian, TOV-21G - in-vitro, Ovarian, SKOV3
tumCV↓, TumCP↓, Apoptosis↑, ChemoSen↑, Gal-3↓, Dose↝,
8892- MOR,  Cisplatin,    Morin Hydrate Reverses Cisplatin Resistance by Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular Carcinoma
- vitro+vivo, HCC, NA
PARP↓, HMGB1↓, ChemoSen↑,
8891- MOR,  Cisplatin,    Morin Hydrate Sensitizes Hepatoma Cells and Xenograft Tumor towards Cisplatin by Downregulating PARP-1-HMGB1 Mediated Autophagy
- in-vitro, Liver, HepG2
PARP1↓, HMGB1↓, Beclin-1/ATG6?,
8918- MP,  Cisplatin,    Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling
- in-vitro, BC, T47D - in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-231
Dose?, TumCP↓, DNAdam↑, TumCCA↑, PRL↓, JAK2↓, STAT5↓, cycD1/CCND1↓, ChemoSen↑,
8770- MSM,  Cisplatin,    Methylsulfonylmethane (MSM) Mitigates Cisplatin-Induced Early Oxidative Testicular Dysfunction Through Modulation of Antioxidant Defense and GPX4 Response
- in-vivo, Nor, NA
*Dose?, *lipid-P↓, *SOD↑, *Catalase↑, *GPx↑, *testos↑, *GPx4↓, *chemoP↑,
8809- MT/VAE,  Cisplatin,    Synergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models
- in-vitro, BC, MDA-MB-231
TumCP↓, Apoptosis↑, TumCCA↑, VEGF↓, Hif1a↓,
2043- PB,  Cisplatin,    Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
- in-vitro, HNSCC, UM-SCC-1
ChemoSen↑, eff↑, HDAC↓, BRCA1↓, RadioS↑,
4920- PEITC,  Cisplatin,    PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p
- vitro+vivo, NSCLC, A549
TumCG↓, ChemoSen↑, cMyc↓, PI3K↓, Akt↓, mTOR↓, BioAv↝, tumCV↓, ChemoSen↑,
5183- PEITC,  Cisplatin,    Phenethyl Isothiocyanate Induces Apoptosis Through ROS Generation and Caspase-3 Activation in Cervical Cancer Cells
- in-vitro, Cerv, HeLa - in-vitro, Nor, HaCaT
DNAdam↑, Apoptosis↑, ChemoSen↑, ROS↑, mt-ROS↑, Casp↑, Casp3↑, selectivity↑, TumCP↓, tumCV↓, eff↓,
4965- PSO,  Cisplatin,    The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis
- vitro+vivo, GC, HGC27 - vitro+vivo, GC, MKN45
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, *toxicity↓, Synergy↑, Ferroptosis↑, ACSL4↑, GPx4↓, ChemoSen↑, chemoP↑, AntiTum↑, Sepsis↓,
4704- PTS,  Cisplatin,    Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS
- in-vitro, Bladder, NA
PI3K↓, mTOR↓, P70S6K↓, MEK↑, ERK↑, ChemoSen↑, TumAuto↑,
1491- RES,  doxoR,  Cisplatin,    Resveratrol Augments Doxorubicin and Cisplatin Chemotherapy: A Novel Therapeutic Strategy
- in-vivo, Var, NA
RadioS↑, ChemoSen↑,
5041- SAS,  Cisplatin,    Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism
- in-vitro, CRC, NA
xCT/SLC7A11↓, Inflam↓, Apoptosis↓, GSH↓, ROS↑, TumCG↓, selectivity↑, eff↑, eff↓,
2182- SK,  Cisplatin,    Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway
- in-vitro, Lung, A549 - in-vitro, Lung, PC9 - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, PKM2↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, TumVol↓, TumW↓, GLUT1↓,
2184- SK,  Cisplatin,    PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
- in-vitro, CRC, T24/HTB-9
PKM2↓, ChemoSen↑, Necroptosis↑,
2008- SK,  Cisplatin,    Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
ChemoSen↑, selectivity↑, i-ROS↑, DNAdam↑, MMP↓, TumCCA↑, eff↓, *toxicity↓,
5330- TFdiG,  Cisplatin,    Theaflavin-3,3′-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, OVCAR-3
selectivity↑, ChemoSen↑, DNAdam↑, GSH↓, CTR1↑,
2133- TQ,  CUR,  Cisplatin,    Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling
- in-vitro, Nor, HEK293 - in-vivo, NA, NA
*creat↓, *TNF-α↓, *IL6↓, *MRP↓, *GFR↑, *mt-ATPase↑, *p‑Akt↑, *NRF2↑, *HO-1↑, *Casp3↓, *NF-kB↓, *RenoP↑,
2116- TQ,  Cisplatin,    Oral administration of Nigella sativa oil ameliorates the effect of cisplatin on membrane enzymes, carbohydrate metabolism and oxidative damage in rat liver
- in-vivo, Nor, NA
*hepatoP↑, *antiOx↑, *ROS↓, ALAT↓, AST↓,
2099- TQ,  Cisplatin,    Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
- in-vitro, Lung, H460 - in-vitro, Lung, H146 - in-vivo, NA, NA
ChemoSen↑, TumCP↓, tumCV↓, Apoptosis↑, NF-kB↓,
4887- ZER,  Rad,  Cisplatin,    Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma
- in-vitro, HNSCC, CAL27
Apoptosis↑, ChemoSen↑, RadioS↑, tumCV↓,

Showing Research Papers: 51 to 94 of 94
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 94

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   Catalase↓, 1,   GPx4↓, 4,   GSH↓, 8,   GSH/GSSG↓, 2,   HO-1↓, 2,   Iron↑, 1,   i-Iron↑, 2,   lipid-P↑, 3,   MDA↓, 1,   i-MDA↑, 1,   NRF2↓, 3,   ROS↓, 1,   ROS↑, 20,   i-ROS↑, 1,   mt-ROS↑, 1,   SOD↓, 2,   SOD↑, 1,   Thiols↓, 1,   TrxR1⇅, 1,   xCT/SLC7A11↓, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   CDC25↓, 1,   mitResp↓, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↑, 2,   ADO↓, 1,   ALAT↓, 1,   i-ATP↓, 1,   BHB↑, 1,   ENO1↓, 1,   FAO↑, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   Histones↑, 1,   HMGCS2↑, 1,   lactateProd↓, 3,   PDK1 / PDPK1↓, 1,   PKM2↓, 2,  

Cell Death(tgid=5) ⓘ

APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 22,   BAX↑, 7,   Bax:Bcl2↑, 2,   Bcl-2↓, 10,   Bcl-xL↓, 1,   Bcl-xL↑, 2,   Casp↑, 3,   cl‑Casp↑, 1,   Casp3↑, 10,   cl‑Casp3↑, 3,   Casp7↑, 3,   Casp8↑, 1,   Casp9↑, 6,   Cyt‑c↑, 2,   Ferroptosis↑, 4,   Mcl-1↓, 2,   Necroptosis↑, 1,   survivin↓, 3,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 6,   p‑Akt↓, 4,   ERK↓, 1,   ERK↑, 1,   JAK↓, 1,   JAK2↓, 2,   JNK↑, 2,   MAPK↓, 2,   MEK↑, 1,   mTOR↓, 3,   P70S6K↓, 1,   PI3K↓, 5,   p‑PI3K↓, 1,   PI3K/Akt↓, 2,   STAT3↓, 4,   STAT5↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 1,   cMyc↓, 1,   HATs↓, 1,   HDAC↓, 2,   KCNQ1OT1↓, 1,   miR-497↑, 1,   other↓, 1,   tumCV↓, 14,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6?, 1,   Beclin-1/ATG6↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   ATR↑, 1,   BRCA1↓, 2,   DNAdam↑, 8,   Ku70/XRCC6↓, 1,   P53↑, 7,   p‑P53↑, 1,   PARP↓, 1,   PARP↑, 2,   cl‑PARP↑, 1,   PARP1↓, 1,   cl‑PARP1↑, 1,   PCNA↓, 1,   SIRT6↓, 1,   XRCC1↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   CDK4/6↓, 1,   Cyc↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   Ki-67↓, 2,   P21↑, 4,   p27/CDKN1B↑, 1,   TumCCA?, 1,   TumCCA↓, 1,   TumCCA↑, 13,   β-Tubulin↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Ki-67↓, 2,   Let-7↑, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   TumCG↓, 7,   TumCP↓, 14,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↓, 1,   E-cadherin↑, 3,   EMT↓, 2,   MMP11↓, 1,   MMP2↓, 1,   MMP9↓, 4,   N-cadherin↓, 1,   Sharpin↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 2,   TumCMig↓, 5,   Vim↓, 1,   Zeb1↓, 1,   ZEB2↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

CD31/PECAM-1↓, 1,   HIF-1↓, 1,   Hif1a↓, 2,   NO↓, 1,   TBXAS1/TxAS↓, 1,   VEGF↓, 4,  

Barriers & Transport(tgid=15) ⓘ

CTR1↑, 1,   GLUT1↓, 2,   MMP↓, 7,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD8+↑, 1,   COX2/PTGS2↓, 5,   Gal-3↓, 1,   HMGB1↓, 2,   IFN-γ↑, 1,   IL1β↓, 2,   IL4↓, 1,   IL6↓, 2,   Inflam↓, 2,   NF-kB↓, 7,   PD-L1↓, 1,   T-Cell↑, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PRL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↑, 56,   Dose?, 2,   Dose↝, 9,   eff↓, 5,   eff↑, 6,   eff↝, 1,   MDR1↓, 2,   MRP1/ABCC1↓, 1,   P-gp/ABCB1↓, 1,   RadioS↑, 6,   selectivity↑, 8,   Synergy↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   BRCA1↓, 2,   E6↓, 1,   E7↓, 1,   IL6↓, 2,   LDH↝, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   antiNeop↑, 1,   AntiTum↑, 2,   cachexia↓, 1,   chemoP↑, 9,   hepatoP↑, 1,   Nausea∅, 1,   NP/CIPN↝, 1,   OS∅, 1,   QoL↑, 1,   RenoP↑, 7,   toxicity↓, 2,   toxicity↝, 2,   TumVol↓, 3,   TumW↓, 2,   Vomit∅, 1,   Weight?, 1,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,  
Total Targets: 206

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 6,   Catalase↑, 1,   GPx↑, 2,   GPx4↓, 1,   GSH↑, 2,   HO-1↑, 5,   Iron↓, 2,   lipid-P↓, 3,   MDA↓, 3,   MPO↓, 1,   NOX4↓, 1,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 6,   ROS↓, 13,   i-ROS↑, 1,   SOD↑, 4,   SOD1↑, 1,   TAC↑, 2,   uricA↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MFN2↑, 1,   mtDam↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   ATP↑, 1,   KeyT↝, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 4,   Bax:Bcl2↓, 1,   Casp3↓, 2,   Casp3∅, 1,   Casp9↓, 1,   Casp9∅, 1,   Cyt‑c↓, 1,   Cyt‑c∅, 1,   Ferroptosis↓, 3,   iNOS↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑Akt↑, 1,   ERK↓, 1,   JNK↓, 1,   MAPK↓, 2,   MAPK↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   P53↑, 1,   PARP∅, 1,   SIRT6↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

IGF-1↑, 1,  

Migration(tgid=13) ⓘ

mt-ATPase↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 2,  

Barriers & Transport(tgid=15) ⓘ

MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL12↓, 1,   IL2↓, 1,   IL6↓, 4,   Inflam↓, 5,   M2 MC↑, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 4,   TNF-α↓, 5,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

testos↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose?, 2,   Dose↝, 2,   MRP↓, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALB↝, 1,   BUN↓, 3,   creat↓, 5,   IL6↓, 4,   KeyT↝, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 6,   GFR↑, 1,   hepatoP↑, 2,   RenoP↑, 7,   toxicity↓, 4,   toxicity↝, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 78

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:197  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page